Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04150965
Title Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Multiple Myeloma Research Consortium
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Emory University Atlanta Georgia 30322 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
University of Michigan Ann Arbor Michigan 48109 United States Details
Washington University School of Medicine Division of Medical Oncology Saint Louis Missouri 63110 United States Details
Hackensack Meridian Medical Center Hackensack New Jersey 07601 United States Details
Mount Sinai School of Medicine New York New York 10029 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Levine Cancer Institute Charlotte North Carolina 28204 United States Details
UT Southwestern Medical Center Dallas Texas 75390 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field